WHO Reference Panel
1st WHO International Reference Panel for HIV-1 p24 Antigen
NIBSC code: 16/210
Instructions for use
(Version 2.0, Dated 24/12/2019)

1. INTENDED USE
The 1st International Reference Panel for HIV-1 p24 Antigen (NIBSC code 16/210), contains a diverse collection of HIV-1 p24 Virus Like Particles (VLPs) derived from clinical isolates [1]; representing subtypes A1, B, C, D, G, H, circulating recombinant forms (CRFs); F1/CRF12_BF/BFrec, CRF20_BG, CRF01_AE, CRF02_AG, and a group O. Panel members were diluted in citrated negative human plasma and cryopreserved in 1 mL aliquots and stored at -20 °C.

The panel was evaluated in a worldwide collaborative study involving 15 laboratories performing a range of HIV immunoassays [2].

This panel is intended for the use with 4th generation combination/antigen only immunoassays and rapid tests to evaluate/validate the sensitivity and specificity to detect HIV-1 p24 antigen.

2. CAUTION
This preparation is not for administration to humans or animals in the human food chain.

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA.

These preparations contain material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE
Each panel member has been assigned a concentration in International Units (IU) when reconstituted in 1 mL of nuclease-free water, based on the results of a worldwide collaborative study [2].

<table>
<thead>
<tr>
<th>NIBSC Code</th>
<th>Subtype</th>
<th>(IU/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16/212</td>
<td>A1</td>
<td>8.8</td>
</tr>
<tr>
<td>16/214</td>
<td>B</td>
<td>7.9</td>
</tr>
<tr>
<td>16/216</td>
<td>C</td>
<td>8.4</td>
</tr>
<tr>
<td>16/218</td>
<td>D</td>
<td>11.5</td>
</tr>
<tr>
<td>16/220</td>
<td>F1/CRF12_BF/BFrec</td>
<td>12.7</td>
</tr>
<tr>
<td>16/222</td>
<td>G</td>
<td>8.0</td>
</tr>
<tr>
<td>16/226</td>
<td>CRF20_BG</td>
<td>9.9</td>
</tr>
<tr>
<td>16/228</td>
<td>CRF01_AE</td>
<td>10.3</td>
</tr>
<tr>
<td>16/230</td>
<td>CRF02_AG</td>
<td>4.0</td>
</tr>
<tr>
<td>16/232</td>
<td>H</td>
<td>6.0</td>
</tr>
<tr>
<td>16/234</td>
<td>group O</td>
<td>11.3</td>
</tr>
</tbody>
</table>

4. CONTENTS
Country of origin of biological material: United Kingdom.

The final material was formulated and produced in the UK, diluent plasma was from a UK source: However, Virus Like particles contained within the panel originate from Switzerland.

5. STORAGE
This panel should be stored at -20 °C upon receipt.

Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING
Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL
No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution.

The materials should be reconstituted with 1 mL of deionized, nuclease-free molecular-grade water and left for a minimum of 20 minutes with occasional agitation before use.

8. STABILITY
Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label. It is the policy of WHO not to assign an expiry date to their international reference materials. Accelerated degradation studies have indicated that the material is suitably stable, when stored at -20 °C until the material is withdrawn or replaced. These studies have also shown that the material is suitably stable for shipment at ambient temperatures without loss of performance.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

10. ACKNOWLEDGEMENTS
Not applicable

11. FURTHER INFORMATION
Further information can be obtained as follows:
This material: enquiries@nibsc.org
WHO Biological Standards:
http://www.who.int/biologicals/en/
JCTLM Higher order reference materials:
http://www.bipm.org/en/committees/jc/tlm/
Derivation of International Units:
http://www.nibsc.org/standards/international_standards.aspx
Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK
Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION
In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC
14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical appearance:</strong></td>
<td>Lyophilised</td>
<td></td>
</tr>
<tr>
<td><strong>Corrosive:</strong></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td><strong>Stable:</strong></td>
<td>Yes</td>
<td>Oxidising: No</td>
</tr>
<tr>
<td><strong>Hygroscopic:</strong></td>
<td>No</td>
<td>Irritant: No</td>
</tr>
<tr>
<td><strong>Flammable:</strong></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td><strong>Other (specify):</strong></td>
<td>Contains citrated human plasma</td>
<td></td>
</tr>
</tbody>
</table>

**Toxicological properties**

- Effects of inhalation: Not established, avoid inhalation
- Effects of ingestion: Not established, avoid ingestion
- Effects of skin absorption: Not established, avoid contact with skin

**Suggested First Aid**

- Inhalation: Seek medical advice
- Ingestion: Seek medical advice
- Contact with eyes: Wash with copious amounts of water. Seek medical advice
- Contact with skin: Wash thoroughly with water.

**Action on Spillage and Method of Disposal**

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

- **Country of origin for customs purposes**: United Kingdom
  - Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
- **Net weight**: 1g
- **Toxicity Statement**: Non-toxic
- **Veterinary certificate or other statement if applicable, Attached**: No

17. CERTIFICATE OF ANALYSIS

NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_biologicalstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.